Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Solara Active Pharma Sciences Limited
EIR
•Solara Active Pharma Sciences Limited•April 17, 2017

Solara Active Pharma Sciences Limited – FDA EIR, Apr 17, 2017

Record Details

An FDA inspection was conducted at Strides Shasun Limited's Cuddalore API Site, a manufacturer of non-sterile active pharmaceutical ingredients and intermediate drug products, from April 17-21, 2017. This comprehensive review assessed the facility's adherence to Current Good Manufacturing Practices (CGMP) and pre-approval requirements. The inspection was carried out under regulatory frameworks including Compliance Programs 7352.832 (Pre-Approval Inspections/Methods Validation) and 7356.002F (Bulk Pharmaceutical Chemicals), in conjunction with ICH Q7 Good Manufacturing Practice Guidance for APIs. Key systems evaluated included quality, facility and equipment, materials, production, packaging, labeling, and laboratory controls. A significant outcome of this inspection was the confirmation that the firm had successfully corrected observations from a previous June 2014 inspection. Prior issues had included ineffective product quality review, lack of corrective and preventive action (CAPA) follow-up for complaints, inconsistent adherence to Out-of-Specification (OOS) procedures, and failure to conduct stability studies on reworked API batches. Crucially, the 2017 inspection concluded without issuing any formal FDA-483 Inspectional Observations. Minor discussions with the firm included ensuring smooth surfaces on roughing and scooping tools, for which the company promptly implemented change control actions. Additionally, clarity was established regarding the primary location for specific analytical testing (IC equipment for assay) to be conducted at their formulation site for future quality control release. The inspection affirmed data integrity, commercial readiness, and compliance with drug master files and applications, resulting in a "No Action Indicated" classification.

Company
Solara Active Pharma Sciences Limited
Inspection date
April 17, 2017
Product type
drugs
Office
Office of Regulatory Affairs
People
  • Kham Phommachanh (Investigator)
  • Karen G. Sego (other)
  • Kevin A. Gonzalez (Branch Chief, Foreign Pharmaceutical Quality Inspection at FDA)
  • Jeneen A. Huff-Robersone (issuing_officer)
View Company Profile

ID · b52dee6b-7a2a-4bd6-be54-cb3191b49960

Violation Codes1
21 CFR 211

Full citation text and observation details available on the Dashboard.

Other documents for Solara Active Pharma Sciences Limited
  • 483 - 2020-03-07March 7, 2020
  • EIR - 2019-07-05July 5, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Solara Active Pharma Sciences Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.